Ira M Longini,
Professor
About Ira M Longini
Dr. Longini received his Ph.D. in Biometry at the University of Minnesota in 1977. He began his career with the International Center for Medical Research and Training and the Universidad del Valle in Cali, Colombia, where he worked on tropical infectious disease problems and taught courses in biomathematics. Following that, he was a professor biostatistics at the University of Michigan, Emory University and the University of Washington. He currently is a professor of biostatistics at the University of Florida and Director of the Center for Statistical and Quantitative Infectious Diseases (CSQUID), the Emerging Pathogens Institute, at the University of Florida. His research interests are in the area of stochastic processes applied to epidemiological problems. He has specialized in the mathematical and statistical theory of epidemics–a process that involves constructing and analyzing mathematical models of disease transmission, disease progression and the analysis of infectious disease data based on these models. He works extensively in the design and analysis of vaccine and infectious disease prevention trials and observational studies. Dr. Longini has worked on the analysis of epidemics of COVID-19, Ebola, mpox, influenza, HIV, tuberculosis, cholera, dengue fever, and other infectious diseases. Dr. Longini is also working with the Department of Health and Human Services, the World Health Organization, the CDC and other public health organizations on mathematical and statistical models for the control of a possible bioterrorist attack with an infectious agent such as smallpox, and other natural infectious disease threats such as COVID-19, pandemic influenza or another coronavirus. Dr. Longini is author or coauthor of over 256 scientific papers and he has won a number of awards for excellence in research, including the Howard M. Temin Award in Epidemiology for “Scientific Excellence in the Fight against HIV/AIDS,” two CDC Statistical Science Awards for both “Best Theoretical and Applied Papers,” the CDC James H. Nakano Citation “for an outstanding scientific publications” the Science Magazine, one of the top 10 “Breakthrough of the Year” for 2015, Guinea Ebola ring vaccination trial, the Aspen Institute Italia Award for scientific research and collaboration between Italy and the United States, 2016, and the David A. Paulus Lifetime Achievement Award, College of Medicine, University of Florida. April 25, 2022. He is a Fellow of the American Statistical Association and a Fellow of the American Association for the Advancement of Science. Dr. Longini has Erdős number = 3.
Additional Positions:
Visiting Scientist
2023 – Current
·
Center for Health Emergencies, Bruno Kessler Foundation, Trento, Italy
High-level consultant
2014 – 2025
·
World Health Organization
Accomplishments
David A. Paulus Lifetime Achievement Award
2022
·
College of Medicine, University of Florida
UF College of Medicine’s Term Professor for leadership in his discipline 2018-2021
2020
·
College of Medicine, UF
UF Research Foundation Professor for excellence in research202
2020
·
University of Florida
National Geographic top 20 Scientific Discoveries of the Decade “Changing the course of disease: In response to the 2014-2016 Ebola outbreak in West Africa, public health officials and the pharmaceutical company Merck fast-tracked rVSV-ZEBOV, an experimental Ebola vaccine. After a highly successful field trial in 2015, European officials approved the vaccine in 2019—a milestone in the fight against the deadly disease National Geographic
2019
·
National Geographic
Altmetic Top 100 Scientific Papers of 2017: Rank #9 for Henao-Restrepo A-M, Camacho A, Longini IM, et al.: Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). The Lancet 389, 505-18 (2017). https://www.altmetric.com/top100/2017/#list&article=14949611
2017
·
Altmetric
Aspen Institute Italia Award for scientific research and collaboration between Italy and the United States, 2016. For outstanding research on Ebola transmission and control.
2016
·
Aspen Foundation
International Society for Vaccines: “Paper of the Year 2015.” Henao-Restrepo, A-M, Longini IM, Egger M, Dean NE et al.: Efficacy of a recombinant live VSV-vectored vaccine expressing Ebola surface glycoprotein: Interim results from the Guinea ring vaccination cluster-randomized trial. The Lancet, 38, 857–866 (2015). http://www.isv-online.org/menu-annual-congress/previos-papers/2015-paper-of-the-months/171-paper-of-the-year-2015
2015
·
International Society for Vaccines
Science Magazine, one of the top 10 “Breakthrough of the Year” for 2015. Guinea Ebola ring vaccination trial: http://www.sciencemag.org/news/2015/12/and-science-s-breakthrough-year
2015
·
Journal: Science
Elected Fellow of the American Association for the Advancement of Science (AAAS)
2012
·
America Association for the Advancement of Science (AAAS)
CDC Statistical Science Award "Best Applied Paper" published in 1996. Satten, G.A. and Longini, I.M.: “Markov chains with measurement error: estimating the "true" course of a marker of HIV disease progression (with discussion)”. Applied Statistics 45, 275-309 (1996)
1996
·
US Centers for Disease Control and Prevention
Elected Fellow of the American Statistical Association
1995
·
American Statistical Association
CDC James H. Nakano Citation "for an outstanding scientific paper published in 1994." Mastro, T.D., Satten, G.A., Nopkesorn, T., Sangkharomya, S. and Longini, I.M.: Probability of female to male transmission of HIV 1 in Thailand. Lancet 343, 204 207 (1994).
1994
·
US Centers for Disease Control and Prevention
CDC Statistical Science Award "Best Theoretical Paper" published in 1994. Satten, G.A. and Longini, I.M.: Estimation of incidence of HIV infection using cross sectional marker surveys. Biometrics 50, 675 688 (1994).
1994
·
US Centers for Disease Control and Prevention
Howard M. Temin Award in Epidemiology for Scientific Excellence in the Fight Against HIV/AIDS (1995) for the article: Jacquez, J.A., Koopman, J.S., Simon, C.P. and Longini, I.M.: The role of primary infection in the epidemics of HIV infection in gay cohorts. Journal of AIDS 7, 1169 1184 (1994
1994
·
Jouranl of Aids
Teaching Profile
Courses Taught
2013,2016-2018,2018-2023,2020-2024,2023-2024
PHC6937 Special Topics in Public Health
2012-2018,2023-2024
PHC7979 Advanced Research
2015-2017,2022-2024,2024
PHC7980 Research for Doctoral Dissertation
2014
PHC7910 International Field Epidemiology
2014
STA7179 Survival Analysis
2023-2024
PHC6905 Independent Study
Research Profile
Open Researcher and Contributor ID (ORCID)
0000-0002-2780-9382
Publications
2024
A systematic review and meta-analysis on the effectiveness of bivalent mRNA booster vaccines against Omicron variants.
Vaccine.
42(15):3389-3396
[DOI] 10.1016/j.vaccine.2024.04.049.
[PMID] 38653679.
2024
Agent-based modeling of the COVID-19 pandemic in Florida.
Epidemics.
47
[DOI] 10.1016/j.epidem.2024.100774.
[PMID] 38852547.
2024
Changing COVID-19 cases and deaths detection in Florida.
PloS one.
19(3)
[DOI] 10.1371/journal.pone.0299143.
[PMID] 38547145.
2024
Evaluating targeted COVID-19 vaccination strategies with agent-based modeling
PLOS Computational Biology.
20(5)
[DOI] 10.1371/journal.pcbi.1012128.
[PMID] 38820570.
2024
Hypothesis testing and sample size considerations for the test-negative design.
BMC medical research methodology.
24(1)
[DOI] 10.1186/s12874-024-02277-4.
[PMID] 39014324.
2024
Methods for the estimation of direct and indirect vaccination effects by combining data from individual‐ and cluster‐randomized trials
Statistics in Medicine.
43(8):1627-1639
[DOI] 10.1002/sim.10030.
2024
The decline of the 2022 Italian mpox epidemic: Role of behavior changes and control strategies.
Nature communications.
15(1)
[DOI] 10.1038/s41467-024-46590-4.
[PMID] 38480715.
2023
Covariate-constrained randomization with cluster selection and substitution
Clinical Trials.
20(3):284-292
[DOI] 10.1177/17407745231160556.
[PMID] 36932663.
2023
Effectiveness of SARS-CoV-2 vaccines against Omicron infection and severe events: a systematic review and meta-analysis of test-negative design studies.
Frontiers in public health.
11
[DOI] 10.3389/fpubh.2023.1195908.
[PMID] 37361171.
2023
Estimates of Serial Interval and Reproduction Number of Sudan Virus, Uganda, August-November 2022.
Emerging infectious diseases.
29(7):1429-1432
[DOI] 10.3201/eid2907.221718.
[PMID] 37347815.
2023
Estimating the impact of COVID-19 vaccine inequities: a modeling study.
Nature communications.
14(1)
[DOI] 10.1038/s41467-023-39098-w.
[PMID] 37277329.
2023
Evaluating targeted COVID-19 vaccination strategies with agent-based modeling.
medRxiv : the preprint server for health sciences.
[DOI] 10.1101/2023.03.09.23285319.
[PMID] 36945423.
2023
Evaluation of the US COVID-19 Scenario Modeling Hub for informing pandemic response under uncertainty.
Nature communications.
14(1)
[DOI] 10.1038/s41467-023-42680-x.
[PMID] 37985664.
2023
Hypothesis testing and sample size considerations for the test-negative design.
Research square.
[DOI] 10.21203/rs.3.rs-3783493/v1.
[PMID] 38234799.
2023
Interactions among acute respiratory viruses in Beijing, Chongqing, Guangzhou, and Shanghai, China, 2009-2019.
Influenza and other respiratory viruses.
17(11)
[DOI] 10.1111/irv.13212.
[PMID] 37964991.
2023
Multimodeling approach to evaluating the efficacy of layering pharmaceutical and nonpharmaceutical interventions for influenza pandemics.
Proceedings of the National Academy of Sciences of the United States of America.
120(28)
[DOI] 10.1073/pnas.2300590120.
[PMID] 37399393.
2023
Quantifying the value of viral genomics when inferring who infected whom in the 2014-16 Ebola virus outbreak in Guinea.
Virus evolution.
9(1)
[DOI] 10.1093/ve/vead007.
[PMID] 36926449.
2023
Rapid review and meta-analysis of serial intervals for SARS-CoV-2 Delta and Omicron variants.
BMC infectious diseases.
23(1)
[DOI] 10.1186/s12879-023-08407-5.
[PMID] 37365505.
2022
A platform trial design for preventive vaccines against Marburg virus and other emerging infectious disease threats
Clinical Trials.
19(6):647-654
[DOI] 10.1177/17407745221110880.
[PMID] 35866633.
2022
An introduction to the Marburg virus vaccine consortium, MARVAC.
PLoS pathogens.
18(10)
[DOI] 10.1371/journal.ppat.1010805.
[PMID] 36227853.
2022
Estimating the impact of COVID-19 vaccine allocation inequities: a modeling study.
medRxiv : the preprint server for health sciences.
[DOI] 10.1101/2022.11.18.22282514.
[PMID] 36415459.
2022
Evolutionary consequences of delaying intervention for monkeypox.
Lancet (London, England).
400(10359):1191-1193
[DOI] 10.1016/S0140-6736(22)01789-5.
[PMID] 36152668.
2022
Household secondary attack rates of SARS-CoV-2 by variant and vaccination status: an updated systematic review and meta-analysis.
medRxiv : the preprint server for health sciences.
[DOI] 10.1101/2022.01.09.22268984.
[PMID] 35043125.
2022
Household Secondary Attack Rates of SARS-CoV-2 by Variant and Vaccination Status: An Updated Systematic Review and Meta-analysis.
JAMA network open.
5(4)
[DOI] 10.1001/jamanetworkopen.2022.9317.
[PMID] 35482308.
2022
Quantifying the importance and location of SARS-CoV-2 transmission events in large metropolitan areas.
Proceedings of the National Academy of Sciences of the United States of America.
119(26)
[DOI] 10.1073/pnas.2112182119.
[PMID] 35696558.
2022
The ring vaccination trial design for the estimation of vaccine efficacy and effectiveness during infectious disease outbreaks.
Clinical trials (London, England).
19(4):402-406
[DOI] 10.1177/17407745211073594.
[PMID] 35057647.
2022
Updated projections for COVID-19 omicron wave in Florida.
medRxiv : the preprint server for health sciences.
[DOI] 10.1101/2022.01.06.22268849.
[PMID] 35018391.
2021
Considerations in boosting COVID-19 vaccine immune responses.
Lancet (London, England).
398(10308):1377-1380
[DOI] 10.1016/S0140-6736(21)02046-8.
[PMID] 34534516.
2021
COVID-19 vaccine trials: The potential for “hybrid” analyses.
Clinical trials (London, England).
18(4):391-397
[DOI] 10.1177/17407745211018613.
[PMID] 34041932.
2021
COVID-19 vaccine trials: The use of active controls and non-inferiority studies.
Clinical trials (London, England).
18(3):335-342
[DOI] 10.1177/1740774520988244.
[PMID] 33535811.
2021
Cryptic transmission of SARS-CoV-2 and the first COVID-19 wave in Europe and the United States.
medRxiv : the preprint server for health sciences.
[DOI] 10.1101/2021.03.24.21254199.
[PMID] 33791745.
2021
Cryptic transmission of SARS-CoV-2 and the first COVID-19 wave.
Nature.
600(7887):127-132
[DOI] 10.1038/s41586-021-04130-w.
[PMID] 34695837.
2021
Factors Associated With Household Transmission of SARS-CoV-2: An Updated Systematic Review and Meta-analysis.
JAMA network open.
4(8)
[DOI] 10.1001/jamanetworkopen.2021.22240.
[PMID] 34448865.
2021
Household transmission of SARS-CoV-2 and risk factors for susceptibility and infectivity in Wuhan: a retrospective observational study.
The Lancet. Infectious diseases.
21(5):617-628
[DOI] 10.1016/S1473-3099(20)30981-6.
[PMID] 33476567.
2021
Inferring high-resolution human mixing patterns for disease modeling.
Nature communications.
12(1)
[DOI] 10.1038/s41467-020-20544-y.
[PMID] 33436609.
2021
Placebo-Controlled Trials of Covid-19 Vaccines – Why We Still Need Them.
The New England journal of medicine.
384(2)
[DOI] 10.1056/NEJMp2033538.
[PMID] 33264543.
2021
SARS-CoV-2 Variants and Vaccines.
The New England journal of medicine.
385(2):179-186
[DOI] 10.1056/NEJMsr2105280.
[PMID] 34161052.
2021
Using simulated infectious disease outbreaks to inform site selection and sample size for individually randomized vaccine trials during an ongoing epidemic.
Clinical trials (London, England).
18(5):630-638
[DOI] 10.1177/17407745211028898.
[PMID] 34218667.
2020
Achieving coordinated national immunity and cholera elimination in Haiti through vaccination: a modelling study.
The Lancet. Global health.
8(8):e1081-e1089
[DOI] 10.1016/S2214-109X(20)30310-7.
[PMID] 32710864.
2020
COVID-19 vaccine trials should seek worthwhile efficacy.
Lancet (London, England).
396(10253):741-743
[DOI] 10.1016/S0140-6736(20)31821-3.
[PMID] 32861315.
2020
Creating a Framework for Conducting Randomized Clinical Trials during Disease Outbreaks.
The New England journal of medicine.
382(14):1366-1369
[DOI] 10.1056/NEJMsb1905390.
[PMID] 32242365.
2020
Designing a Study of Correlates of Risk for Ebola Vaccination.
American journal of epidemiology.
189(8):747-754
[DOI] 10.1093/aje/kwaa001.
[PMID] 31971229.
2020
Designing effective control of dengue with combined interventions.
Proceedings of the National Academy of Sciences of the United States of America.
117(6):3319-3325
[DOI] 10.1073/pnas.1903496117.
[PMID] 31974303.
2020
Ensemble forecast modeling for the design of COVID-19 vaccine efficacy trials.
Vaccine.
38(46):7213-7216
[DOI] 10.1016/j.vaccine.2020.09.031.
[PMID] 33012602.
2020
Estimating the establishment of local transmission and the cryptic phase of the COVID-19 pandemic in the USA.
medRxiv : the preprint server for health sciences.
[DOI] 10.1101/2020.07.06.20140285.
[PMID] 32676609.
2020
Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study.
The Lancet. Infectious diseases.
20(7):793-802
[DOI] 10.1016/S1473-3099(20)30230-9.
[PMID] 32247326.
2020
Evolving epidemiology of novel coronavirus diseases 2019 and possible interruption of local transmission outside Hubei Province in China: a descriptive and modeling study.
medRxiv : the preprint server for health sciences.
[DOI] 10.1101/2020.02.21.20026328.
[PMID] 32511424.
2020
Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a retrospective cohort study.
The Lancet. Infectious diseases.
20(10):1141-1150
[DOI] 10.1016/S1473-3099(20)30471-0.
[PMID] 32562601.
2020
Household Secondary Attack Rate of COVID-19 and Associated Determinants.
medRxiv : the preprint server for health sciences.
[DOI] 10.1101/2020.04.11.20056010.
[PMID] 32511590.
2020
Household transmission of SARS-CoV-2: a systematic review and meta-analysis of secondary attack rate.
medRxiv : the preprint server for health sciences.
[DOI] 10.1101/2020.07.29.20164590.
[PMID] 32766596.
2020
Household Transmission of SARS-CoV-2: A Systematic Review and Meta-analysis.
JAMA network open.
3(12)
[DOI] 10.1001/jamanetworkopen.2020.31756.
[PMID] 33315116.
2020
Modeling the impact of social distancing, testing, contact tracing and household quarantine on second-wave scenarios of the COVID-19 epidemic.
medRxiv : the preprint server for health sciences.
[DOI] 10.1101/2020.05.06.20092841.
[PMID] 32511536.
2020
Modelling the impact of testing, contact tracing and household quarantine on second waves of COVID-19.
Nature human behaviour.
4(9):964-971
[DOI] 10.1038/s41562-020-0931-9.
[PMID] 32759985.
2020
Temporal Confounding in the Test-Negative Design.
American journal of epidemiology.
189(11):1402-1407
[DOI] 10.1093/aje/kwaa084.
[PMID] 32415834.
2020
The effect of travel restrictions on the spread of the 2019 novel coronavirus (2019-nCoV) outbreak.
medRxiv : the preprint server for health sciences.
[DOI] 10.1101/2020.02.09.20021261.
[PMID] 32511423.
2020
The effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-19) outbreak
Science.
368(6489):395-400
[DOI] 10.1126/science.aba9757.
[PMID] 32144116.
2020
The TIRS trial: protocol for a cluster randomized controlled trial assessing the efficacy of preventive targeted indoor residual spraying to reduce Aedes-borne viral illnesses in Merida, Mexico.
Trials.
21(1)
[DOI] 10.1186/s13063-020-04780-7.
[PMID] 33032661.
2019
An online decision tree for vaccine efficacy trial design during infectious disease epidemics: The InterVax-Tool.
Vaccine.
37(31):4376-4381
[DOI] 10.1016/j.vaccine.2019.06.019.
[PMID] 31242963.
2019
Design of vaccine efficacy trials during public health emergencies
Science Translational Medicine.
11(499)
[DOI] 10.1126/scitranslmed.aat0360.
[PMID] 31270270.
2019
Determinants of Transmission Risk During the Late Stage of the West African Ebola Epidemic.
American journal of epidemiology.
188(7):1319-1327
[DOI] 10.1093/aje/kwz090.
[PMID] 30941398.
2019
Effects of infection history on dengue virus infection and pathogenicity.
Nature communications.
10(1)
[DOI] 10.1038/s41467-019-09193-y.
[PMID] 30886145.
2019
Genomic epidemiology supports multiple introductions and cryptic transmission of Zika virus in Colombia.
BMC infectious diseases.
19(1)
[DOI] 10.1186/s12879-019-4566-2.
[PMID] 31718580.
2018
Biofilms Comprise a Component of the Annual Cycle of Vibrio cholerae in the Bay of Bengal Estuary.
mBio.
9(2)
[DOI] 10.1128/mBio.00483-18.
[PMID] 29666284.
2018
Dengue seroprevalence in a cohort of schoolchildren and their siblings in Yucatan, Mexico (2015-2016).
PLoS neglected tropical diseases.
12(11)
[DOI] 10.1371/journal.pntd.0006748.
[PMID] 30462654.
2018
Dependency of Vaccine Efficacy on Preexposure and Age: A Closer Look at a Tetravalent Dengue Vaccine.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
66(2):178-184
[DOI] 10.1093/cid/cix766.
[PMID] 29020332.
2018
DESIGN OF VACCINE TRIALS DURING OUTBREAKS WITH AND WITHOUT A DELAYED VACCINATION COMPARATOR.
The annals of applied statistics.
12(1):330-347
[DOI] 10.1214/17-AOAS1095.
[PMID] 29606991.
2018
Epidemiology of dengue and other arboviruses in a cohort of school children and their families in Yucatan, Mexico: Baseline and first year follow-up.
PLoS neglected tropical diseases.
12(11)
[DOI] 10.1371/journal.pntd.0006847.
[PMID] 30462635.
2018
Forecasting the effectiveness of indoor residual spraying for reducing dengue burden.
PLoS neglected tropical diseases.
12(6)
[DOI] 10.1371/journal.pntd.0006570.
[PMID] 29939983.
2018
Intermediate levels of vaccination coverage may minimize seasonal influenza outbreaks.
PloS one.
13(6)
[DOI] 10.1371/journal.pone.0199674.
[PMID] 29944709.
2018
Quantifying the risk of local Zika virus transmission in the contiguous US during the 2015-2016 ZIKV epidemic.
BMC medicine.
16(1)
[DOI] 10.1186/s12916-018-1185-5.
[PMID] 30336778.
2018
Questionable efficacy of the rVSV-ZEBOV Ebola vaccine – Authors’ reply.
Lancet (London, England).
391(10125):1021-1022
[DOI] 10.1016/S0140-6736(18)30559-2.
[PMID] 29565012.
2018
Reply to Aguiar and Stollenwerk.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
66(4)
[DOI] 10.1093/cid/cix883.
[PMID] 29088434.
2018
Seroprevalence of Dengue Antibodies in Three Urban Settings in Yucatan, Mexico.
The American journal of tropical medicine and hygiene.
98(4):1202-1208
[DOI] 10.4269/ajtmh.17-0382.
[PMID] 29460714.
2018
Spatio-temporal coherence of dengue, chikungunya and Zika outbreaks in Merida, Mexico.
PLoS neglected tropical diseases.
12(3)
[DOI] 10.1371/journal.pntd.0006298.
[PMID] 29543910.
2018
Transmissibility of Norovirus in Urban Versus Rural Households in a Large Community Outbreak in China.
Epidemiology (Cambridge, Mass.).
29(5):675-683
[DOI] 10.1097/EDE.0000000000000855.
[PMID] 29847497.
2017
Controlling cholera in the Ouest Department of Haiti using oral vaccines.
PLoS neglected tropical diseases.
11(4)
[DOI] 10.1371/journal.pntd.0005482.
[PMID] 28410382.
2017
Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!).
Lancet (London, England).
389(10068):505-518
[DOI] 10.1016/S0140-6736(16)32621-6.
[PMID] 28017403.
2017
Live-attenuated tetravalent dengue vaccines: The needs and challenges of post-licensure evaluation of vaccine safety and effectiveness.
Vaccine.
35(42):5535-5542
[DOI] 10.1016/j.vaccine.2017.08.066.
[PMID] 28893477.
2017
Ring vaccination with rVSV-ZEBOV under expanded access in response to an outbreak of Ebola virus disease in Guinea, 2016: an operational and vaccine safety report.
The Lancet. Infectious diseases.
17(12):1276-1284
[DOI] 10.1016/S1473-3099(17)30541-8.
[PMID] 29033032.
2017
Simulations for designing and interpreting intervention trials in infectious diseases.
BMC medicine.
15(1)
[DOI] 10.1186/s12916-017-0985-3.
[PMID] 29287587.
2017
Spread of Zika virus in the Americas.
Proceedings of the National Academy of Sciences of the United States of America.
114(22):E4334-E4343
[DOI] 10.1073/pnas.1620161114.
[PMID] 28442561.
2017
The public health value of vaccines beyond efficacy: methods, measures and outcomes.
BMC medicine.
15(1)
[DOI] 10.1186/s12916-017-0911-8.
[PMID] 28743299.
2016
Changes in the primary outcome in Ebola vaccine trial–Authors’ reply.
Lancet (London, England).
387(10027):1509-1510
[DOI] 10.1016/S0140-6736(16)00686-3.
[PMID] 27115974.
2016
Containing Ebola at the Source with Ring Vaccination.
PLoS neglected tropical diseases.
10(11)
[DOI] 10.1371/journal.pntd.0005093.
[PMID] 27806049.
2016
Correction: Cholera Transmission in Ouest Department of Haiti: Dynamic Modeling and the Future of the Epidemic.
PLoS neglected tropical diseases.
10(1)
[DOI] 10.1371/journal.pntd.0004377.
[PMID] 26736014.
2016
Extrapolating theoretical efficacy of inactivated influenza A/H5N1 virus vaccine from human immunogenicity studies.
Vaccine.
34(33):3796-802
[DOI] 10.1016/j.vaccine.2016.05.067.
[PMID] 27268778.
2016
Molecular Infectious Disease Epidemiology: Survival Analysis and Algorithms Linking Phylogenies to Transmission Trees.
PLoS computational biology.
12(4)
[DOI] 10.1371/journal.pcbi.1004869.
[PMID] 27070316.
2016
PREDICTIVE MODELING OF CHOLERA OUTBREAKS IN BANGLADESH.
The annals of applied statistics.
10(2):575-595
[PMID] 27746850.
2016
Projected Impact of Dengue Vaccination in Yucatán, Mexico.
PLoS neglected tropical diseases.
10(5)
[DOI] 10.1371/journal.pntd.0004661.
[PMID] 27227883.
2016
Quantifying the Epidemiological Impact of Vector Control on Dengue.
PLoS neglected tropical diseases.
10(5)
[DOI] 10.1371/journal.pntd.0004588.
[PMID] 27227829.
2016
Spatiotemporal dynamics of the Ebola epidemic in Guinea and implications for vaccination and disease elimination: a computational modeling analysis.
BMC medicine.
14(1)
[DOI] 10.1186/s12916-016-0678-3.
[PMID] 27600737.
2016
The epidemiology and transmissibility of Zika virus in Girardot and San Andres island, Colombia, September 2015 to January 2016.
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
21(28)
[DOI] 10.2807/1560-7917.ES.2016.21.28.30283.
[PMID] 27452806.
2016
The Long-Term Safety, Public Health Impact, and Cost-Effectiveness of Routine Vaccination with a Recombinant, Live-Attenuated Dengue Vaccine (Dengvaxia): A Model Comparison Study.
PLoS medicine.
13(11)
[DOI] 10.1371/journal.pmed.1002181.
[PMID] 27898668.
2016
Transmissibility and Pathogenicity of Ebola Virus: A Systematic Review and Meta-analysis of Household Secondary Attack Rate and Asymptomatic Infection.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
62(10):1277-1286
[DOI] 10.1093/cid/ciw114.
[PMID] 26932131.
2016
Transmission dynamics of Ebola virus disease and intervention effectiveness in Sierra Leone.
Proceedings of the National Academy of Sciences of the United States of America.
113(16):4488-93
[DOI] 10.1073/pnas.1518587113.
[PMID] 27035948.
2015
Cholera Transmission in Ouest Department of Haiti: Dynamic Modeling and the Future of the Epidemic.
PLoS neglected tropical diseases.
9(10)
[DOI] 10.1371/journal.pntd.0004153.
[PMID] 26488620.
2015
Ebola vaccination – Authors’ reply.
Lancet (London, England).
386(10012)
[DOI] 10.1016/S0140-6736(15)00951-4.
[PMID] 26738716.
2015
Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial.
Lancet (London, England).
386(9996):857-66
[DOI] 10.1016/S0140-6736(15)61117-5.
[PMID] 26248676.
2015
Household transmissibility of avian influenza A (H7N9) virus, China, February to May 2013 and October 2013 to March 2014.
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
20(10)
[PMID] 25788253.
2015
Increased isolation frequency of toxigenic Vibrio cholerae O1 from environmental monitoring sites in Haiti.
PloS one.
10(4)
[DOI] 10.1371/journal.pone.0124098.
[PMID] 25853552.
2015
One versus two doses: What is the best use of vaccine in an influenza pandemic?
Epidemics.
13:17-27
[DOI] 10.1016/j.epidem.2015.06.001.
[PMID] 26616038.
2015
Spatiotemporal spread of the 2014 outbreak of Ebola virus disease in Liberia and the effectiveness of non-pharmaceutical interventions: a computational modelling analysis.
The Lancet. Infectious diseases.
15(2):204-11
[DOI] 10.1016/S1473-3099(14)71074-6.
[PMID] 25575618.
2015
The contribution of neighbours to an individual’s risk of typhoid outcome.
Epidemiology and infection.
143(16):3520-7
[DOI] 10.1017/S0950268815000692.
[PMID] 25936682.
2015
The dengue vaccine pipeline: Implications for the future of dengue control.
Vaccine.
33(29):3293-8
[DOI] 10.1016/j.vaccine.2015.05.010.
[PMID] 25989449.
2015
Vaccine testing. Ebola and beyond.
Science (New York, N.Y.).
348(6230):46-8
[DOI] 10.1126/science.aaa3178.
[PMID] 25838371.
2014
Assessing the Impact of Travel Restrictions On International Spread of the 2014 West African Ebola Epidemic
Eurosurveillance.
19(42):8-13
2014
Assessing the impact of travel restrictions on international spread of the 2014 West African Ebola epidemic.
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
19(42)
[PMID] 25358040.
2014
Assessing the international spreading risk associated with the 2014 west african ebola outbreak.
PLoS currents.
6
[DOI] 10.1371/currents.outbreaks.cd818f63d40e24aef769dda7df9e0da5.
[PMID] 25642360.
2014
Comparative effectiveness of different strategies of oral cholera vaccination in bangladesh: a modeling study.
PLoS neglected tropical diseases.
8(12)
[DOI] 10.1371/journal.pntd.0003343.
[PMID] 25473851.
2014
Ebola: mobility data.
Science (New York, N.Y.).
346(6208)
[DOI] 10.1126/science.346.6208.433-a.
[PMID] 25342792.
2014
Emerging, evolving, and established infectious diseases and interventions.
Science (New York, N.Y.).
345(6202):1292-4
[DOI] 10.1126/science.1254166.
[PMID] 25214617.
2014
Genetic variation of Vibrio cholerae during outbreaks, Bangladesh, 2010-2011.
Emerging infectious diseases.
20(1):54-60
[DOI] 10.3201/eid2001.130796.
[PMID] 24377372.
2014
Household Transmission of Vibrio cholerae in Bangladesh.
PLoS neglected tropical diseases.
8(11)
[DOI] 10.1371/journal.pntd.0003314.
[PMID] 25411971.
2014
Modeling cholera outbreaks.
Current topics in microbiology and immunology.
379:195-209
[DOI] 10.1007/82_2013_307.
[PMID] 23412687.
2014
School-located influenza vaccination reduces community risk for influenza and influenza-like illness emergency care visits.
PloS one.
9(12)
[DOI] 10.1371/journal.pone.0114479.
[PMID] 25489850.
2013
Have the explosive HIV epidemics in sub-Saharan Africa been driven by higher community viral load?
AIDS (London, England).
27(15):2494-6
[DOI] 10.1097/01.aids.0000432463.23508.a2.
[PMID] 24029738.
2013
Have the explosive HIV epidemics in sub-Saharan Africa been driven by higher community viral load?
AIDS (London, England).
27(6):981-989
[DOI] 10.1097/QAD.0b013e32835cb927.
[PMID] 23196933.
2013
Optimal vaccine allocation for the early mitigation of pandemic influenza.
PLoS computational biology.
9(3)
[DOI] 10.1371/journal.pcbi.1002964.
[PMID] 23555207.
2013
The effects of vector movement and distribution in a mathematical model of dengue transmission.
PloS one.
8(10)
[DOI] 10.1371/journal.pone.0076044.
[PMID] 24204590.
2013
Understanding HIV epidemics: aggregate viral load metrics and ‘smoking guns’.
AIDS (London, England).
27(17):2826-7
[DOI] 10.1097/QAD.0000000000000002.
[PMID] 24384634.
2012
A hybrid EM and Monte Carlo EM algorithm and its application to analysis of transmission of infectious diseases.
Biometrics.
68(4):1238-49
[DOI] 10.1111/j.1541-0420.2012.01757.x.
[PMID] 22506893.
2012
A Mathematical Model for the Control of Dengue Using Vaccines
International Journal of Infectious Diseases.
16
[DOI] 10.1016/j.ijid.2012.05.985.
2012
A theoretic framework to consider the effect of immunizing schoolchildren against influenza: implications for research.
Pediatrics.
129 Suppl 2:S63-7
[DOI] 10.1542/peds.2011-0737D.
[PMID] 22383483.
2012
Assessing the potential of a candidate dengue vaccine with mathematical modeling.
PLoS neglected tropical diseases.
6(3)
[DOI] 10.1371/journal.pntd.0001450.
[PMID] 22479655.
2012
Controlling dengue with vaccines in Thailand.
PLoS neglected tropical diseases.
6(10)
[DOI] 10.1371/journal.pntd.0001876.
[PMID] 23145197.
2012
Critical immune and vaccination thresholds for determining multiple influenza epidemic waves.
Epidemics.
4(1):22-32
[DOI] 10.1016/j.epidem.2011.11.003.
[PMID] 22325011.
2012
ESTIMATING WITHIN-SCHOOL CONTACT NETWORKS TO UNDERSTAND INFLUENZA TRANSMISSION.
The annals of applied statistics.
6(1):1-26
[PMID] 22639701.
2012
The global spread of drug-resistant influenza.
Journal of the Royal Society, Interface.
9(69):648-56
[DOI] 10.1098/rsif.2011.0427.
[PMID] 21865253.
2011
ESTIMATING WITHIN-HOUSEHOLD CONTACT NETWORKS FROM EGOCENTRIC DATA.
The annals of applied statistics.
5(3):1816-1838
[PMID] 22427793.
2011
Hand, foot, and mouth disease in China: patterns of spread and transmissibility.
Epidemiology (Cambridge, Mass.).
22(6):781-92
[DOI] 10.1097/EDE.0b013e318231d67a.
[PMID] 21968769.
2011
Planning for the control of pandemic influenza A (H1N1) in Los Angeles County and the United States.
American journal of epidemiology.
173(10):1121-30
[DOI] 10.1093/aje/kwq497.
[PMID] 21427173.
2011
The effect of age on transmission of 2009 pandemic influenza A (H1N1) in a camp and associated households.
Epidemiology (Cambridge, Mass.).
22(2):180-7
[DOI] 10.1097/EDE.0b013e3182060ca5.
[PMID] 21233714.
2011
The global transmission and control of influenza.
PloS one.
6(5)
[DOI] 10.1371/journal.pone.0019515.
[PMID] 21573121.
2011
Vaccination strategies for epidemic cholera in Haiti with implications for the developing world.
Proceedings of the National Academy of Sciences of the United States of America.
108(17):7081-5
[DOI] 10.1073/pnas.1102149108.
[PMID] 21482756.
2010
El Tor cholera with severe disease: a new threat to Asia and beyond.
Epidemiology and infection.
138(3):347-52
[DOI] 10.1017/S0950268809990550.
[PMID] 19678971.
2010
FluTE, a publicly available stochastic influenza epidemic simulation model.
PLoS computational biology.
6(1)
[DOI] 10.1371/journal.pcbi.1000656.
[PMID] 20126529.
2010
Modeling Competing Infectious Pathogens from a Bayesian Perspective: Application to Influenza Studies with Incomplete Laboratory Results.
Journal of the American Statistical Association.
105(492):1310-1322
[PMID] 21472041.
2010
Optimizing vaccine allocation at different points in time during an epidemic.
PloS one.
5(11)
[DOI] 10.1371/journal.pone.0013767.
[PMID] 21085686.
2010
Population level impact of an imperfect prophylactic vaccine for herpes simplex virus-2.
Sexually transmitted diseases.
37(5):290-7
[DOI] 10.1097/OLQ.0b013e3181d3d023.
[PMID] 20351622.
2010
School opening dates predict pandemic influenza A(H1N1) outbreaks in the United States.
The Journal of infectious diseases.
202(6):877-80
[DOI] 10.1086/655810.
[PMID] 20704486.
2010
Studies needed to address public health challenges of the 2009 H1N1 influenza pandemic: insights from modeling.
PLoS medicine.
7(6)
[DOI] 10.1371/journal.pmed.1000275.
[PMID] 20532237.
2010
Towards a quantitative understanding of the within-host dynamics of influenza A infections.
Journal of the Royal Society, Interface.
7(42):35-47
[DOI] 10.1098/rsif.2009.0067.
[PMID] 19474085.
2009
A Bayesian model for evaluating influenza antiviral efficacy in household studies with asymptomatic infections.
Biostatistics (Oxford, England).
10(2):390-403
[DOI] 10.1093/biostatistics/kxn045.
[PMID] 19202152.
2009
A/H1N1 flu pandemic. Antiviral drugs: distinguish treatment from prophylaxis.
BMJ (Clinical research ed.).
339
[DOI] 10.1136/bmj.b3620.
[PMID] 19737833.
2009
Antiviral resistance and the control of pandemic influenza: the roles of stochasticity, evolution and model details.
Journal of theoretical biology.
256(1):117-25
[DOI] 10.1016/j.jtbi.2008.09.021.
[PMID] 18952105.
2009
Economic evaluation of influenza pandemic mitigation strategies in the United States using a stochastic microsimulation transmission model.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
12(2):226-33
[DOI] 10.1111/j.1524-4733.2008.00437.x.
[PMID] 18671770.
2009
Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics.
Proceedings of the National Academy of Sciences of the United States of America.
106(33):13980-5
[DOI] 10.1073/pnas.0901720106.
[PMID] 19666590.
2009
Intervention strategies for an influenza pandemic taking into account secondary bacterial infections.
Epidemics.
1(3):185-95
[DOI] 10.1016/j.epidem.2009.09.001.
[PMID] 20161493.
2009
Public health. The cholera crisis in Africa.
Science (New York, N.Y.).
324(5929)
[DOI] 10.1126/science.1173890.
[PMID] 19443768.
2009
Quantitative assessment of the role of male circumcision in HIV epidemiology at the population level.
Epidemics.
1(3):139-52
[DOI] 10.1016/j.epidem.2009.08.001.
[PMID] 21352761.
2009
Strategies for pandemic and seasonal influenza vaccination of schoolchildren in the United States.
American journal of epidemiology.
170(6):679-86
[DOI] 10.1093/aje/kwp237.
[PMID] 19679750.
2009
The transmissibility and control of pandemic influenza A (H1N1) virus.
Science (New York, N.Y.).
326(5953):729-33
[DOI] 10.1126/science.1177373.
[PMID] 19745114.
2008
A Bayesian Framework for Estimating Vaccine Efficacy per Infectious Contact.
The annals of applied statistics.
2(4):1409-1431
[PMID] 19169384.
2008
Estimating influenza vaccine efficacy from challenge and community-based study data.
American journal of epidemiology.
168(12):1343-52
[DOI] 10.1093/aje/kwn259.
[PMID] 18974084.
2008
Genital herpes has played a more important role than any other sexually transmitted infection in driving HIV prevalence in Africa.
PloS one.
3(5)
[DOI] 10.1371/journal.pone.0002230.
[PMID] 18493617.
2008
Modeling targeted layered containment of an influenza pandemic in the United States.
Proceedings of the National Academy of Sciences of the United States of America.
105(12):4639-44
[DOI] 10.1073/pnas.0706849105.
[PMID] 18332436.
2008
No HIV stage is dominant in driving the HIV epidemic in sub-Saharan Africa.
AIDS (London, England).
22(9):1055-61
[DOI] 10.1097/QAD.0b013e3282f8af84.
[PMID] 18520349.
2007
A Data-Augmentation Method for Infectious Disease Incidence Data from Close Contact Groups.
Computational statistics & data analysis.
51(12):6582-6595
[PMID] 18704156.
2007
A Resampling-Based Test to Detect Person-To-Person Transmission of Infectious Disease.
The annals of applied statistics.
1(1):211-228
[PMID] 19436773.
2007
Analytic insights into the population level impact of imperfect prophylactic HIV vaccines.
Journal of acquired immune deficiency syndromes (1999).
45(4):454-67
[PMID] 17554215.
2007
Antiviral effects on influenza viral transmission and pathogenicity: observations from household-based trials.
American journal of epidemiology.
165(2):212-21
[PMID] 17088311.
2007
Containing a large bioterrorist smallpox attack: a computer simulation approach.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
11(2):98-108
[PMID] 16899385.
2007
Controlling endemic cholera with oral vaccines.
PLoS medicine.
4(11)
[PMID] 18044983.
2007
Detecting human-to-human transmission of avian influenza A (H5N1).
Emerging infectious diseases.
13(9):1348-53
[DOI] 10.3201/eid1309.070111.
[PMID] 18252106.
2007
Efficacy of trivalent, cold-adapted, influenza virus vaccine against influenza A (Fujian), a drift variant, during 2003-2004.
Vaccine.
25(20):4038-45
[PMID] 17395338.
2007
Neuraminidase inhibitor resistance in influenza: assessing the danger of its generation and spread.
PLoS computational biology.
3(12)
[PMID] 18069885.
2007
What is the best control strategy for multiple infectious disease outbreaks?
Proceedings. Biological sciences.
274(1611):833-7
[PMID] 17251095.
2006
Design and Evaluation of Prophylactic Interventions Using Infectious Disease Incidence Data from Close Contact Groups.
Journal of the Royal Statistical Society. Series C, Applied statistics.
55(3):317-330
[PMID] 22457545.
2006
Mitigation strategies for pandemic influenza in the United States.
Proceedings of the National Academy of Sciences of the United States of America.
103(15):5935-40
[PMID] 16585506.
2006
Public health. Community studies for vaccinating schoolchildren against influenza.
Science (New York, N.Y.).
311(5761):615-6
[PMID] 16456066.
2005
Containing pandemic influenza at the source.
Science (New York, N.Y.).
309(5737):1083-7
[PMID] 16079251.
2005
Critical factors influencing the occurrence of Vibrio cholerae in the environment of Bangladesh.
Applied and environmental microbiology.
71(8):4645-54
[PMID] 16085859.
2005
Finding optimal vaccination strategies for pandemic influenza using genetic algorithms.
Journal of theoretical biology.
234(2):201-12
[PMID] 15757679.
2005
Population-wide benefits of routine vaccination of children against influenza.
Vaccine.
23(10):1284-93
[PMID] 15652671.
2005
Preclinical assessment of HIV vaccines and microbicides by repeated low-dose virus challenges.
PLoS medicine.
2(8)
[PMID] 16018721.
2005
Strategy for distribution of influenza vaccine to high-risk groups and children.
American journal of epidemiology.
161(4):303-6
[PMID] 15692073.
2004
Containing pandemic influenza with antiviral agents.
American journal of epidemiology.
159(7):623-33
[PMID] 15033640.
2004
Direct and total effectiveness of the intranasal, live-attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A(H1N1) and B epidemic in healthy children.
Archives of pediatrics & adolescent medicine.
158(1):65-73
[PMID] 14706961.
2004
Safety of cold-adapted live influenza vaccine.
The Pediatric infectious disease journal.
23(6):593-4; author reply 594
[PMID] 15194854.
2003
A 4-year study of the epidemiology of Vibrio cholerae in four rural areas of Bangladesh.
The Journal of infectious diseases.
187(1):96-101
[PMID] 12508151.
2003
Estimating efficacy of trivalent, cold-adapted, influenza virus vaccine (CAIV-T) against influenza A (H1N1) and B using surveillance cultures.
American journal of epidemiology.
158(4):305-11
[PMID] 12915495.
2003
The critical vaccination fraction for heterogeneous epidemic models.
Mathematical biosciences.
181(1):85-106
[PMID] 12421553.
2002
Community interventions and the epidemic prevention potential.
Vaccine.
20(27-28):3254-62
[PMID] 12213394.
2002
Containing bioterrorist smallpox.
Science (New York, N.Y.).
298(5597):1428-32
[PMID] 12434061.
2002
Epidemic and endemic cholera trends over a 33-year period in Bangladesh.
The Journal of infectious diseases.
186(2):246-51
[PMID] 12134262.
2002
Model-based estimation of vaccine effects from community vaccine trials.
Statistics in medicine.
21(4):481-95
[PMID] 11836731.
2002
Subtype-specific transmission probabilities for human immunodeficiency virus type 1 among injecting drug users in Bangkok, Thailand.
American journal of epidemiology.
155(2):159-68
[PMID] 11790680.
2001
Nonparametric maximum likelihood estimation for competing risks survival data subject to interval censoring and truncation.
Biometrics.
57(1):74-80
[PMID] 11252621.
2001
Using validation sets for outcomes and exposure to infection in vaccine field studies.
American journal of epidemiology.
154(5):391-8
[PMID] 11532779.
2000
Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control.
Vaccine.
18(18):1902-9
[PMID] 10699339.
2000
Modeling markers of disease progression by a hidden Markov process: application to characterizing CD4 cell decline.
Biometrics.
56(3):733-41
[PMID] 10985209.
1999
A Markov model for measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV vaccines.
Statistics in medicine.
18(1):53-68
[PMID] 9990692.
1999
Design and interpretation of vaccine field studies.
Epidemiologic reviews.
21(1):73-88
[PMID] 10520474.
1999
Efficiency of estimating vaccine efficacy for susceptibility and infectiousness: randomization by individual versus household.
Biometrics.
55(3):792-8
[PMID] 11315008.
1999
Semiparametric methods for multiple exposure mismeasurement and a bivariate outcome in HIV vaccine trials.
Biometrics.
55(1):94-101
[PMID] 11318183.
1998
Augmented HIV vaccine trial design for estimating reduction in infectiousness and protective efficacy.
Statistics in medicine.
17(2):185-200
[PMID] 9483728.
1998
Estimation of vaccine efficacy in the presence of waning: application to cholera vaccines.
American journal of epidemiology.
147(10):948-59
[PMID] 9596473.
1998
Optimal vaccine trial design when estimating vaccine efficacy for susceptibility and infectiousness from multiple populations.
Statistics in medicine.
17(10):1121-36
[PMID] 9618773.
1998
Semi-parametric models for mismeasured exposure information in vaccine trials.
Statistics in medicine.
17(20):2335-52
[PMID] 9819831.
1997
Study designs for evaluating different efficacy and effectiveness aspects of vaccines.
American journal of epidemiology.
146(10):789-803
[PMID] 9384199.
1996
Estimability and interpretation of vaccine efficacy using frailty mixing models.
American journal of epidemiology.
144(1):83-97
[PMID] 8659489.
1996
Measuring vaccine efficacy for both susceptibility to infection and reduction in infectiousness for prophylactic HIV-1 vaccines.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
13(5):440-7
[PMID] 8970471.
1996
Use of immunological markers and continuous-time Markov models to estimate progression of HIV infection in homosexual men.
AIDS (London, England).
10(6):649-56
[PMID] 8780820.
1995
AIDS: modeling epidemic control.
Science (New York, N.Y.).
267(5202):1250-1; author reply 1252
[PMID] 7871414.
1995
The effect of disease prior to an outbreak on estimates of vaccine efficacy following the outbreak.
American journal of epidemiology.
141(10):980-90
[PMID] 7741128.
1994
Estimation of incidence of HIV infection using cross-sectional marker surveys.
Biometrics.
50(3):675-88
[PMID] 7981394.
1994
Exposure efficacy and change in contact rates in evaluating prophylactic HIV vaccines in the field.
Statistics in medicine.
13(4):357-77
[PMID] 8177986.
1994
Modelling the female-to-male per-act HIV transmission probability in an emerging epidemic in Asia.
Statistics in medicine.
13(19-20):2097-106
[PMID] 7846413.
1994
Probability of female-to-male transmission of HIV-1 in Thailand.
Lancet (London, England).
343(8891):204-7
[PMID] 7904668.
1994
Role of the primary infection in epidemics of HIV infection in gay cohorts.
Journal of acquired immune deficiency syndromes.
7(11):1169-84
[PMID] 7932084.
1994
The ecological effects of individual exposures and nonlinear disease dynamics in populations.
American journal of public health.
84(5):836-42
[PMID] 8179058.
1993
Effect of routine use of therapy in slowing the clinical course of human immunodeficiency virus (HIV) infection in a population-based cohort.
American journal of epidemiology.
137(11):1229-40
[PMID] 8100682.
1993
Estimates of the US health impact of influenza.
American journal of public health.
83(12):1712-6
[PMID] 8259800.
1993
Estimation of vaccine efficacy from epidemics of acute infectious agents under vaccine-related heterogeneity.
Mathematical biosciences.
117(1-2):271-81
[PMID] 8400580.
1993
Measuring vaccine efficacy from epidemics of acute infectious agents.
Statistics in medicine.
12(3-4):249-63
[PMID] 8456210.
1992
A discrete-time model for the statistical analysis of infectious disease incidence data.
Biometrics.
48(1):117-28
[PMID] 1316178.
1992
Estimating the stage-specific numbers of HIV infection using a Markov model and back-calculation.
Statistics in medicine.
11(6):831-43
[PMID] 1594820.
1992
Interpretation and estimation of vaccine efficacy under heterogeneity.
American journal of epidemiology.
136(3):328-43
[PMID] 1415152.
1991
A generalized stochastic model for the analysis of infectious disease final size data.
Biometrics.
47(3):961-74
[PMID] 1742449.
1991
A simulation model of AIDS in San Francisco: I. Model formulation and parameter estimation.
Mathematical biosciences.
106(2):203-22
[PMID] 1806102.
1991
Assessing risk factors for transmission of infection.
American journal of epidemiology.
133(12):1199-209
[PMID] 2063828.
1991
Determinants and predictors of dengue infection in Mexico.
American journal of epidemiology.
133(11):1168-78
[PMID] 2035520.
1991
Direct and indirect effects in vaccine efficacy and effectiveness.
American journal of epidemiology.
133(4):323-31
[PMID] 1899778.
1991
Estimation of vaccine efficacy in outbreaks of acute infectious diseases.
Statistics in medicine.
10(10):1573-84
[PMID] 1947513.
1991
Measures of the effects of vaccination in a randomly mixing population.
International journal of epidemiology.
20(1):300-10
[PMID] 2066239.
1991
The dynamics of CD4+ T-lymphocyte decline in HIV-infected individuals: a Markov modeling approach.
Journal of acquired immune deficiency syndromes.
4(11):1141-7
[PMID] 1684387.
1990
[Direct and indirect effects of vaccines: an annotation on the estimation of the vaccine efficacy from outbreaks caused by acute infection agents such as measles].
Boletin medico del Hospital Infantil de Mexico.
47(7):516-9
[PMID] 2206419.
1990
Estimating benefits of screening from observational cohort studies.
Statistics in medicine.
9(8):969-80
[PMID] 2218198.
1990
Modeling the decline of CD4+ T-lymphocyte counts in HIV-infected individuals.
Journal of acquired immune deficiency syndromes.
3(9):930-1
[PMID] 1974629.
1990
Simulation of mechanisms of viral interference in influenza.
International journal of epidemiology.
19(2):444-54
[PMID] 2376460.
1989
Duration of human immunodeficiency virus infection before detection of antibody.
Lancet (London, England).
2(8664):637-40
[PMID] 2570898.
1989
Re: “Use of Modeling in Infectious Disease Epidemiology”.
American journal of epidemiology.
130(3):619-21
[PMID] 2764009.
1989
Statistical analysis of the stages of HIV infection using a Markov model.
Statistics in medicine.
8(7):831-43
[PMID] 2772443.
1989
The Tecumseh Study. XVI: Family and community sources of rotavirus infection.
American journal of epidemiology.
130(4):760-8
[PMID] 2773919.
1988
Efficacy of virucidal nasal tissues in interrupting familial transmission of respiratory agents. A field trial in Tecumseh, Michigan.
American journal of epidemiology.
128(3):639-44
[PMID] 2843040.
1988
Models for the statistical analysis of infectious disease data.
Biometrics.
44(1):163-73
[PMID] 3358986.
1988
Statistical inference for infectious diseases. Risk-specific household and community transmission parameters.
American journal of epidemiology.
128(4):845-59
[PMID] 3421247.
1986
Predicting the global spread of new infectious agents.
American journal of epidemiology.
123(3):383-91
[PMID] 3946385.
1985
Tecumseh study of illness. XIII. Influenza infection and disease, 1976-1981.
American journal of epidemiology.
121(6):811-22
[PMID] 4014174.
1984
Environmental and genetic sources of familial aggregation of blood pressure in Tecumseh, Michigan.
American journal of epidemiology.
120(1):131-44
[PMID] 6741914.
1984
Genetic and environmental sources of familial aggregation of body mass in Tecumseh, Michigan.
Human biology.
56(4):733-57
[PMID] 6530223.
1984
Simulation studies of influenza epidemics: assessment of parameter estimation and sensitivity.
International journal of epidemiology.
13(4):496-501
[PMID] 6519891.
1984
Statistical procedures for estimating the community probability of illness in family studies: rhinovirus and influenza.
International journal of epidemiology.
13(1):99-106
[PMID] 6321368.
1984
The Tecumseh Community Health Study.
Progress in clinical and biological research.
147:43-5
[PMID] 6739493.
1983
[Procedures for estimating transmission parameters from influenza epidemics: use of serological data].
Voprosy virusologii.
(2):176-82
[PMID] 6868556.
1983
Models of epidemics and endemicity in genetically variable host populations.
Journal of mathematical biology.
17(3):289-304
[PMID] 6619663.
1983
The Tecumseh study. XII. Enteric agents in the community, 1976-1981.
The Journal of infectious diseases.
148(2):284-91
[PMID] 6310002.
1982
Estimating household and community transmission parameters for influenza.
American journal of epidemiology.
115(5):736-51
[PMID] 7081204.
1982
Household and community transmission parameters from final distributions of infections in households.
Biometrics.
38(1):115-26
[PMID] 7082755.
Grants
Sep 2023
ACTIVE
Epistorm: Center for Advanced Epidemic Analytics and Predictive Modeling Technology
Role: Principal Investigator
Funding: NORTHEASTERN UNIV
via CTRS FOR DISEASE CONTROL AND PREVENTION
Sep 2023
– Aug 2024
Building mathematical modeling workforce capacity to support infectious disease and healthcare research
Role: Co-Investigator
Funding: UNIVERSITY OF GEORGIA
via CTRS FOR DISEASE CONTROL AND PREVENTION
Jun 2023
– Dec 2023
20223/1362324 – WHO COVID-19
Role: Principal Investigator
Funding: WORLD HLTH ORGANIZATION
Jan 2023
– May 2023
Covid 19 (cont) 2022/1314190-0_PO 203037053: Re: Continued work on clinical trial designs, statistical analysis and clinical evaluation of candidate vaccines and therapeutics to be used during Public Health Emergencies current ongoing COVID-19 pandemic
Role: Principal Investigator
Funding: WORLD HLTH ORGANIZATION
Sep 2022
– Sep 2023
Building mathematical modeling workforce capacity to support infectious disease and healthcare research
Role: Co-Investigator
Funding: CTRS FOR DISEASE CONTROL AND PREVENTION
Sep 2022
ACTIVE
Developing TranStat: A user-friendly R package for the analysis of infectious disease transmission and control among close contacts
Role: Principal Investigator
Funding: UNIVERSITY OF GEORGIA
via NATL INST OF HLTH NIAID
Jan 2022
– Dec 2022
2022 WHO Contract_PI: Longini
Role: Principal Investigator
Funding: WORLD HLTH ORGANIZATION
Aug 2021
– Jul 2023
Design and Analysis of Vaccine Trials for Emerging Infectious Disease Threats
Role: Principal Investigator
Funding: EMORY UNIV
via NATL INST OF HLTH NIAID
Aug 2021
– Jul 2023
Targeted vaccination strategies for COVID-19: A mathematical modeling approach UFF F020981
Role: Principal Investigator
Funding: UF FOUNDATION
via GOLDMAN SACHS PHILANTHROPY FUND
Jun 2021
– May 2023
Targeted vaccination strategies for COVID-19: A mathematical modeling approach
Role: Principal Investigator
Funding: SCHWAB CHARITABLE
via CONWAY FAMILY FOUNDATION
Jan 2021
– Dec 2021
2021 WHO Contract_PI: Longini
Role: Principal Investigator
Funding: WORLD HLTH ORGANIZATION
Sep 2020
– Aug 2022
Mathematical and Statistical Methods for the Control of Global Infectious Disease Threats
Role: Principal Investigator
Funding: NATL INST OF HLTH NIAID
May 2020
– Dec 2020
WHO FY21/ PI: Longini
Role: Principal Investigator
Funding: WORLD HLTH ORGANIZATION
Apr 2020
ACTIVE
Quantifying the Epidemiological Impact of Targeted Indoor Residual Spraying on Aedes-borne Diseases
Role: Principal Investigator
Funding: EMORY UNIV
via NATL INST OF HLTH NIAID
Jan 2020
– Apr 2020
WHO 2020
Role: Principal Investigator
Funding: WORLD HLTH ORGANIZATION
Jun 2019
– Dec 2019
WHO 2019 Agreement_PI: Longini
Role: Principal Investigator
Funding: WORLD HLTH ORGANIZATION
Jun 2019
– May 2020
Yr.6 Methods of Evaluating Vaccine Efficacy
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH NIAID
Aug 2018
– Jul 2021
Design and Analysis of Vaccine Trials for Emerging Infectious Disease Threats
Role: Co-Investigator
Funding: NATL INST OF HLTH NIAID
Jul 2018
– Jun 2019
Center for Statistics and Quantitative Infectious Diseases (CSQUID): Research Project 1 – Modeling, Spacial, Statistics
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH NIGMS
Jul 2018
– Jun 2019
Center for Statistics and Quantitative Infectious Diseases (CSQUID): Research Project 3 – Understanding Transmission with Integrated Genetic and Epidemiologic Inference
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH NIGMS
Jul 2018
– Jun 2019
Center for Statistics and Quantitative Infectious Diseases (CSQUID): Software Development and Core Facilities
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH NIGMS
Jun 2018
– May 2019
Yr.5 Methods of Evaluating Vaccine Efficacy
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH NIAID
Jan 2018
– Dec 2018
WHO 2018 Agreement_PI: Longini
Role: Principal Investigator
Funding: WORLD HLTH ORGANIZATION
Jan 2018
– Dec 2020
Regression, Phylogenetics, and Study Design in Infectious Disease Epidemiology
Role: Co-Investigator
Funding: OHIO STATE UNIV
via NATL INST OF HLTH NIAID
Aug 2017
– May 2018
Methods for Evaluating Vaccine Efficacy Supplement
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH NIAID
Jul 2017
– Jun 2018
Center for Statistics and Quantitative Infectious Diseases (CSQUID): Research Project 1 – Modeling, Spacial, Statistics
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH NIGMS
Jul 2017
– Jun 2018
Center for Statistics and Quantitative Infectious Diseases (CSQUID): Research Project 3 – Understanding Transmission with Integrated Genetic and Epidemiologic Inference
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH NIGMS
Jul 2017
– Jun 2018
CSQUID U54- Software Development_Yr.4
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH NIGMS
Jul 2017
– Sep 2017
To provide technical support to the WHO Blueprint and develop a guidance document for vaccine clinical evaluation in Public Health Emergencies
Role: Other
Funding: WORLD HLTH ORGANIZATION
Jun 2017
– May 2018
Methods of Evaluating Vaccine Efficacy_Yr.4
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH NIAID
May 2017
– Aug 2018
Targeted Vaccination of Children in Urban Slums against Cholera: Evaluation of Potentially Cost effective and Impactful Strategy for Deploying Oral Cholera Vaccine against Endemic Cholera in Bangladesh
Role: Principal Investigator
Funding: INTL CENTRE FOR DIARRHOEAL DISEASE RES
Apr 2017
– Dec 2017
WHO agreement_PI: Longini
Role: Principal Investigator
Funding: WORLD HLTH ORGANIZATION
Jan 2017
– Dec 2021
Dynamics of Influenza Transmission in Nicaraguan Households
Role: Principal Investigator
Funding: UNIV OF MICHIGAN
via NATL INST OF HLTH NIAID
Aug 2016
– Jan 2017
Dengue Vaccine Seroprevalence Surveys
Role: Other
Funding: WORLD HLTH ORGANIZATION
Aug 2016
– Feb 2021
Aspen Award for Scientific Research & Collaboration between Italy and the United States
Role: Principal Investigator
Funding: MISCELLANEOUS DONORS
Jul 2016
– Jun 2017
Center for statistics and quantitative infectious disease (csquid): software development and core facilities
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH
Jul 2016
– Jun 2017
center for statistics and quantitative infectious diseases (csquid): policy studies
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH NIGMS
Jul 2016
– Jun 2017
center for statistics and quantitative infectious diseases (csquid): project 1 modeling , special, statistics
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH NIGMS
Jul 2016
– Jun 2017
center for statistics and quantitative infectious diseases (csquid): research project 3 understanding transmission
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH NIGMS
Jul 2016
– Jun 2017
Zika Study- Center for Statistics and Quantitative Infectious Disease
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH
May 2016
– Apr 2017
Harnessing spatial heterogeneity to contain Zika virus transmission
Role: Principal Investigator
Funding: EMORY UNIV
via NATL SCIENCE FOU
Oct 2015
– Aug 2016
Statistical analysis of the Ebola ring vaccine trial in Guinea
Role: Principal Investigator
Funding: WORLD HLTH ORGANIZATION
Jul 2015
– Jun 2016
Center for Statistics and Quantitative Infectious Diseases
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH NIGMS
Jul 2015
– Jun 2016
Center for Statistics and Quantitative Infectious Diseases (CSQUID): Policy Studies
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH NIGMS
Jul 2015
– Jun 2016
Center for Statistics and Quantitative Infectious Diseases (CSQUID): Research Project 3 – Understanding Transmission with Integrated Genetic and Epidemiologic Inference
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH NIGMS
Jul 2015
– Jun 2016
Center for Statistics and Quantitative Infectious Diseases (CSQUID): Software Development and Core Facilities
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH NIGMS
Jul 2015
– Jun 2016
Center for Statistics and Quantitative Infectious Diseases (CSQUID): Training, Outreach, and Diversity Plans
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH NIGMS
Jun 2015
– May 2018
Spatio-Temporal Modeling for Surveillance Data of Multiple Pathogens
Role: Project Manager
Funding: NATL INST OF HLTH NIAID
Jun 2015
– May 2017
Methods for evaluating vaccine efficacy
Role: Principal Investigator
Funding: FRED HUTCHINSON CANCER CENTER
via NATL INST OF HLTH
May 2014
– Aug 2016
Dengue baseline studies and vaccine efficacy field trials in Yucat?n, Mexico
Role: Principal Investigator
Funding: Universidad Autonoma de Yucatan
via SANOFI
Feb 2014
– Jan 2019
Quantifying the balance between vaccine-induced T cell protection and pathology
Role: Principal Investigator
Funding: EMORY UNIV
via NATL INST OF HLTH NIAID
Apr 2013
– Sep 2016
Dengue Vaccine Initiative
Role: Principal Investigator
Funding: INTERNATIONAL VACCINE INSTITUTE
Dec 2011
– Jun 2016
Cholera Transmission in Gressier Region, Haiti
Role: Project Manager
Funding: NATL INST OF HLTH NIAID
Jun 2010
– May 2017
Epidemiology and Ecology of Vibrio cholerae in Bangladesh
Role: Project Manager
Funding: JOHNS HOPKINS UNIVERSITY
via NATL INST OF HLTH
Education
Ph.D.
1977
·
University of Minnesota
M.Sc.
1973
·
University of Florida
B.Sc.
1971
·
University of Florida
Contact Details
Phones:
- Business:
- (352) 294-1938
Emails:
- Business:
- ilongini@ufl.edu
Addresses:
- Business Mailing:
-
P O BOX 117450
P O BOX 117450
22 BUCKMAN DRIVE, 452 DAUER HALL
GAINESVILLE FL 326110001 - Business Street:
-
228 BUCKMAN DR 452
DAUER HALL
GAINESVILLE FL 32611